|
19.02.2015 22:06:15
|
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
GAITHERSBURG, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2014 financial and operating results after the close of U.S. financial markets on Thursday, February 26, 2015.
In addition, management will host a conference call to discuss the quarterly and year-end financial results and provide an update on corporate activities.
| Conference call details are as follows: | |
| Date: | February 26, 2015 |
| Time: | 4:30 pm US Eastern Time |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) |
| Via web: | www.novavax.com |
| Conference call replay: | |
| Dates: | Starting at 6:31 pm ET on February 26, 2015 until midnight March 5, 2015 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 89629680 |
| Via web: | www.novavax.com, "Investor Info"/"Events" |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, novavax.com.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
240-268-2000
ir@novavax.com
Novavax, Inc.
David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
212-845-4271
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novavax Inc.mehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Novavax Inc.mehr Analysen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.